Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis. The company is also developing a range of assays for tick-borne diseases, such as lyme disease, as well as for use in screening blood for the parasite babesia microti that causes babesiosis; and T-SPOT.CMV test that measures the strength of a patient's cellular response to CMV infection. Oxford Immunotec Global PLC markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors in other parts of the world. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone44-0-12-3544-2780
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$59.75 million
Profitability
Miscellaneous
Employees414
Next Earnings Date5/7/2019 (Estimated)
OptionableNot Optionable
Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions
What is Oxford Immunotec Global's stock symbol?
Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."
How were Oxford Immunotec Global's earnings last quarter?
Oxford Immunotec Global PLC (NASDAQ:OXFD) released its quarterly earnings results on Monday, March, 11th. The company reported $1.25 EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $1.44. The business earned $15.37 million during the quarter, compared to analyst estimates of $18.61 million. Oxford Immunotec Global had a return on equity of 14.26% and a net margin of 147.71%. View Oxford Immunotec Global's Earnings History.
When is Oxford Immunotec Global's next earnings date?
What guidance has Oxford Immunotec Global issued on next quarter's earnings?
Oxford Immunotec Global issued an update on its FY 2019 earnings guidance on Monday, March, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $69-72 million, compared to the consensus revenue estimate of $69.85 million.
What price target have analysts set for OXFD?
2 brokerages have issued twelve-month price objectives for Oxford Immunotec Global's shares. Their forecasts range from $19.00 to $19.00. On average, they anticipate Oxford Immunotec Global's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 7.7% from the stock's current price. View Analyst Price Targets for Oxford Immunotec Global.
What is the consensus analysts' recommendation for Oxford Immunotec Global?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global.
Has Oxford Immunotec Global been receiving favorable news coverage?
Headlines about OXFD stock have been trending positive this week, InfoTrie reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oxford Immunotec Global earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Oxford Immunotec Global's key competitors?
Some companies that are related to Oxford Immunotec Global include Lantheus (LNTH), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Quotient (QTNT), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), ImmuCell (ICCC), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Akers Biosciences (AKER) and Arca Biopharma (ABIO).
What other stocks do shareholders of Oxford Immunotec Global own?
Who are Oxford Immunotec Global's key executives?
Oxford Immunotec Global's management team includes the folowing people:
- Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 45)
- Mr. Richard M. Altieri, Chief Financial Officer (Age 59)
- Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 58)
- Mr. Stefan C. Linn, Chief Operating Officer (Age 54)
- Ms. Karen C. Koski, Head of Strategy & Investor Relations
Who are Oxford Immunotec Global's major shareholders?
Oxford Immunotec Global's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Polar Capital LLP (9.70%), BlackRock Inc. (4.93%), Bellevue Group AG (1.16%), Penn Capital Management Co. Inc. (1.15%), Northern Trust Corp (1.10%) and Stonepine Capital Management LLC (0.84%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.
Which major investors are selling Oxford Immunotec Global stock?
OXFD stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Birchview Capital LP, Bank of America Corp DE, United Services Automobile Association, BlackRock Inc., D. E. Shaw & Co. Inc., Two Sigma Advisers LP and Campbell & CO Investment Adviser LLC. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.
Which major investors are buying Oxford Immunotec Global stock?
OXFD stock was acquired by a variety of institutional investors in the last quarter, including Martingale Asset Management L P, Bellevue Group AG, Oppenheimer & Co. Inc., Millennium Management LLC, Bessemer Group Inc., Polar Capital LLP, Penn Capital Management Co. Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Oxford Immunotec Global.
How do I buy shares of Oxford Immunotec Global?
Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oxford Immunotec Global's stock price today?
One share of OXFD stock can currently be purchased for approximately $17.64.
How big of a company is Oxford Immunotec Global?
Oxford Immunotec Global has a market capitalization of $464.99 million and generates $59.75 million in revenue each year. The company earns $121.28 million in net income (profit) each year or $0.51 on an earnings per share basis. Oxford Immunotec Global employs 414 workers across the globe.
What is Oxford Immunotec Global's official website?
How can I contact Oxford Immunotec Global?
Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]
MarketBeat Community Rating for Oxford Immunotec Global (NASDAQ OXFD)
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.
